NCT01954992 Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
| NCT ID | NCT01954992 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Eleison Pharmaceuticals LLC. |
| Condition | Metastatic Pancreatic Adenocarcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 480 participants |
| Start Date | 2014-04 |
| Primary Completion | 2026-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 3 trials are large pivotal studies comparing the treatment to current standard of care or placebo. Your participation directly contributes to the evidence needed for regulatory approval.
This trial targets 480 participants in total. It began in 2014-04 with a primary completion date of 2026-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is designed to assess whether glufosfamide provides additional survival benefit as compared to bolus 5-FU in patients with metastatic pancreatic cancer who have already progressed or failed therapy on a gemcitabine based first line regimen.
Eligibility Criteria
Inclusion Criteria: * At least 18 years of age * Pancreatic adenocarcinoma proven either by histology (surgical biopsy) or cytology (CT- or endoscopic-guided) * Metastatic pancreatic cancer * Disease progression during or after treatment with gemcitabine (alone or in combination with other agents; at regular, not radiosensitizing, doses) * Measurable or nonmeasurable disease by RECIST criteria (at least one target or nontarget lesion) * Recovered from reversible toxicities of prior therapy * ECOG performance status 0-1 * All women of childbearing potential and all men must agree to use effective means of contraception (surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) from entry into the study through 6 months after the last dose of chemotherapy * Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's IRB/Ethics Committee Exclusion Criteria: * More than one prior systemic therapy regimen for metastatic pancreatic cancer (radiosensitizing doses of 5-FU or gemcitabine at the time of initial radiotherapy do not count as a prior systemic therapy regimen) * Hormonal therapy, radiation therapy, biologic therapy, chemotherapy or other systemic antitumor therapy for pancreatic cancer within 14 days prior to Cycle 1 Day 1 * Insulin-dependent diabetes mellitus (patients with type 2 diabetes controlled with oral glucose lowering agents and the occasional use of insulin are permitted in the study) * Symptomatic brain metastases (baseline CT scan is not required in asymptomatic patients) * Active clinically significant infection requiring antibiotics * Known HIV positive or active hepatitis B or C * Recent (one year) history or symptoms of cardiovascular disease (NYHA Class 2, 3, or 4), particularly coronary artery disease, arrhythmias or conduction defects with risk of cardiovascular instability, uncontrolled hypertension, clinically significant pericardial effusion, or congestive heart failure * No other active malignancies (other than treated non-melanoma skin cancer or treated in situ cancer) within the past year * Major surgery within 3 weeks of the start of study treatment, without complete recovery * Clinically significant abnormalities in laboratory test results (including complete blood count, chemistry panel including electrolytes, and urinalysis) * Hemoglobin \<9 g/dL (may receive transfusion or erythropoietin to maintain) * ANC \<1500/μL * Platelet count \<100,000/μL * Total bilirubin \> 1.5×ULN * AST/ALT \> 2.5-fold above ULN (\>5-fold above ULN if liver metastases) * Phosphorus \< LLN * Potassium \< LLN * Serum creatinine \> 2 mg/dL * Creatinine clearance \< 60 mL/min (calculated by Cockcroft-Gault formula) * Females who are pregnant or breast-feeding * Participation in an investigational drug or device study within 14 days of the first day of dosing on this study * Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the patient in this study * Any medical history, concurrent disease or concomitant medication which could reasonably predispose the patient to renal insufficiency while on study treatment * Contraindication or unwillingness to undergo multiple CT scans * Unwillingness or inability to comply with the study protocol for any other reason
Contact & Investigator
Edwin Thomas
STUDY DIRECTOR
Eleison Pharmaceuticals
Frequently Asked Questions
Who can join the NCT01954992 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Metastatic Pancreatic Adenocarcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT01954992 trial and what does that mean for participants?
Phase 3 trials are large-scale studies comparing the new treatment to existing standards of care or a placebo. They provide the evidence needed for regulatory approval. This trial targets 480 participants.
Is NCT01954992 currently recruiting?
Yes, NCT01954992 is actively recruiting participants. Contact the research team at clinical@eleison-pharma.com for enrollment information.
Where is the NCT01954992 trial being conducted?
This trial is being conducted at Whittier, United States, Tampa, United States, Canton, United States.
Who is sponsoring the NCT01954992 clinical trial?
NCT01954992 is sponsored by Eleison Pharmaceuticals LLC.. The principal investigator is Edwin Thomas at Eleison Pharmaceuticals. The trial plans to enroll 480 participants.